Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus XYLOCAINE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus XYLOCAINE W EPINEPHRINE.
Labetalol vs XYLOCAINE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Lidocaine blocks voltage-gated sodium channels, inhibiting neuronal depolarization and conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging local anesthetic action.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Adults: 1-5 mL of 1% or 2% solution (maximum 7 mg/kg lidocaine without epinephrine; 7 mg/kg with epinephrine; not to exceed 500 mg total) by infiltration or nerve block, not to be repeated within 2 hours.
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Lidocaine terminal half-life: ~1.5-2 hours (initial); ~2-4 hours (terminal) after IV. Prolonged in hepatic dysfunction (up to 5-7 hours) and congestive heart failure (up to 10 hours).
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Renal: lidocaine and metabolites (primarily 4-hydroxyxylidine and glycinexylidide) ~90% as metabolites, <10% unchanged. Biliary/fecal: minor (approximately 3-5%).
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist